VivoSeq
Oncology

Breast Carcinoma

85

Pipeline Programs↗

18

Active Trials↗

37

Companies Involved↗

Breast Carcinoma is a moderately active landscape with 85 programs across 37 companies. The most active players are Syndax Pharmaceuticals, EMD Serono Research & Development Institute, Inc., Bristol-Myers Squibb. 34 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

68/100

Pipeline Velocity

32/100

Mech. Concentration

8/100

Completion Rate

67/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Syndax Pharmaceuticals

1 program

Phase 1EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1P

Provectus Biopharmaceuticals, Inc.

1 program

Phase 1GSK logo

GSK

2 programs

Phase 2O

Oncology Specialties, Alabama

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical15

Epirubicin Hydrochloride

Merck & Co.

Eribulin Mesylate

Eisai

Goserelin Acetate

AstraZeneca

Piqray

Novartis

Capecitabine

Engelhard Arzneimittel GmbH & Co.KG

Phase 17

Entinostat

Syndax Pharmaceuticals

Bintrafusp Alfa

EMD Serono Research & Development Institute, Inc.

Ipilimumab

Bristol-Myers Squibb

PV-10

Provectus Biopharmaceuticals, Inc.

Eftilagimod Alfa

Immutep S.A.S.

Phase 221

Veliparib

AbbVie

Retifanlimab

Incyte

Tucatinib

Pfizer

Alisertib

Takeda

AZD9833

AstraZeneca

Phase 38

ABP 414

Amgen

Paclitaxel

Teva

Trastuzumab

Organon and Co

Atezolizumab

Roche

Durvalumab

AstraZeneca

Approved34

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Fulvestrant

Fresenius Kabi Oncology Ltd.

Osimertinib

AstraZeneca

Gemcitabine

Johnson & Johnson

Lapatinib Ditosylate

Novartis

Analysis

Modality Breakdown

85%

Small molecule

69 of 81 classified programs — the dominant modality here.

15%ALL OTHERSMonoclonal antibody1012%Protein / enzyme22%

Small molecule leads; the ring shows all 81 classified programs, each share of the total. Modality classified for 96% of 89 pipeline programs.

Analysis

Trial Status

35

clinical trials

Completed10 · 29%
Not yet recruiting7 · 20%
Active, not recruiting6 · 17%
Recruiting4 · 11%
Terminated4 · 11%
Unknown status2 · 6%
Other2 · 6%

Clinical Trials

Trial Activity

35 trials

Association of Adjuvant Radiotherapy of Non-metastatic Breast Carcinoma With Immunomodulation and Circulating Tumor Cell Phenotype in Relation to Patient Age.
Recruiting·UUniversity of Jena·N/A·NCT04902937·200 enrolled
Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer
Recruiting·MM.D. Anderson Cancer Center·N/A·NCT05042687·300 enrolled
Open-Label Umbrella Study to Evaluate Safety and Efficacy of Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced or Metastatic Breast Cancer
Recruiting·FFaeth Therapeutics·Preclinical·NCT07558733·32 enrolled
A Randomized Clinical Trial of the LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy
Recruiting·SStanford University·Preclinical·NCT05366699·80 enrolled
A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
Active, not recruiting·Pfizer logoPfizer·Phase 2·NCT04721977·66 enrolled
Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment
Active, not recruiting·UUNICANCER·Phase 3·NCT01564056·1,989 enrolled
A Randomized Controlled Trial Comparing a Genetic Counseling Patient Preference Intervention vs. Conventional Genetic Counseling for Women at Elevated Risk for Breast Cancer
Active, not recruiting·OOhio State University Comprehensive Cancer Center·Preclinical·NCT05325151·874 enrolled
Manual Lymphatic Drainage With Diaphragmatic Breathing Exercises in Post Radical Mastectomy
Active, not recruiting·University of Lahore·Preclinical·NCT07676045·58 enrolled
The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer
Active, not recruiting·DDana-Farber Cancer Institute·Phase 2·NCT02653755·671 enrolled
CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer
Active, not recruiting·AAbramson Cancer Center at Penn Medicine·Phase 2·NCT03032406·53 enrolled
Multimodal Imaging With FAPI-PET/MRI in Breast Carcinoma-In-Situ for Detection of Occult Invasive Cancer
Not yet recruiting·UUniversität Münster·Phase 2·NCT06540872·30 enrolled
Assessing the Effect of an Aerobic Exercise Program on Vascular Function in Women With Non-Metastatic Breast Cancer
Not yet recruiting·LLoyola University·Preclinical·NCT07517224·40 enrolled
Precision Prevention: Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care
Not yet recruiting·CCity of Hope Medical Center·N/A·NCT07690852·423 enrolled
The Effect of Animation Video and Training Booklet Designed on Breast Cancer in Palestinian Women on Screening Methods
Not yet recruiting·IIstanbul University·Preclinical·NCT07676812·128 enrolled
Effects of Core-Focused Exercise Training and Kinesiology Taping Combined With Complex Decongestive Physiotherapy on Posture, Pain, Function, and Quality of Life in Women With Breast Cancer-Related Lymphedema
Not yet recruiting·HHacettepe University·Preclinical·NCT07673939·46 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)